Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on June 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). CEO Jasbir Seehra scheduled for Goldman Sachs Global Healthcare Conference fireside chat on June 8, 2026 at 4:00 p.m. ET.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CEO Jasbir Seehra scheduled for Goldman Sachs Global Healthcare Conference fireside chat on June 8, 2026 at 4:00 p.m. ET
- Investor focus likely on Keros’ pipeline, clinical development, funding outlook, and strategic priorities
- Presentation furnished under Regulation FD, enabling broad public access without Section 18 filing liability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.